
Shaogui Wan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10814602/publications.pdf Version: 2024-02-01



<u> Снаосці Мам</u>

#	Article	IF	CITATIONS
1	Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression. Oncogene, 2019, 38, 5007-5020.	2.6	119
2	Genetic Polymorphisms in Pre-microRNA Genes as Prognostic Markers of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 217-227.	1.1	74
3	Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. PLoS ONE, 2012, 7, e47687.	1.1	67
4	Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Scientific Reports, 2016, 6, 23992.	1.6	66
5	Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. European Journal of Cancer, 2012, 48, 1014-1022.	1.3	52
6	Preoperative Platelet Count Associates with Survival and Distant Metastasis in Surgically Resected Colorectal Cancer Patients. Journal of Gastrointestinal Cancer, 2013, 44, 293-304.	0.6	49
7	Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma. EBioMedicine, 2020, 56, 102811.	2.7	40
8	GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. European Journal of Cancer, 2011, 47, 1699-1707.	1.3	38
9	Association between leukocyte telomere length and glioma risk: a case-control study. Neuro-Oncology, 2014, 16, 505-512.	0.6	36
10	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. European Journal of Cancer, 2019, 106, 133-143.	1.3	35
11	Potentially functional genetic variants in <i>KDR</i> gene as prognostic markers in patients with resected colorectal cancer. Cancer Science, 2012, 103, 561-568.	1.7	31
12	Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis <scp>B</scp> virus infection. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 131-138.	1.4	31
13	Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma. Oncogene, 2020, 39, 1724-1738.	2.6	30
14	Functional polymorphisms in the <i>NPAS2</i> gene are associated with overall survival in transcatheter arterial chemoembolizationâ€treated hepatocellular carcinoma patients. Cancer Science, 2014, 105, 825-832.	1.7	26
15	Increased Drp1 promotes autophagy and ESCC progression by mtDNA stress mediated cGAS-STING pathway. Journal of Experimental and Clinical Cancer Research, 2022, 41, 76.	3.5	22
16	Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection – Results from a clinic-based longitudinal cohort. European Journal of Cancer, 2012, 48, 2319-2327.	1.3	21
17	Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer, 2013, 13, 340.	1.1	21
18	Telomere length in circulating serum <scp>DNA</scp> as a novel nonâ€invasive biomarker for cirrhosis: a nested case–control analysis. Liver International, 2012, 32, 1233-1241.	1.9	20

Shaogui Wan

#	Article	IF	CITATIONS
19	Donor Plasma Mitochondrial DNA Is Correlated with Posttransplant Renal Allograft Function. Transplantation, 2019, 103, 2347-2358.	0.5	20
20	Alterations of telomere length and mtDNA copy number are associated with overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Cancer Chemotherapy and Pharmacology, 2016, 78, 791-799.	1.1	18
21	Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection. Oncology Letters, 2018, 16, 3499-3508.	0.8	15
22	Circulating Mitochondrial DNA Content Associated with the Risk of Liver Cirrhosis: A Nested Case–Control Study. Digestive Diseases and Sciences, 2015, 60, 1707-1715.	1.1	14
23	Characterization of fragment sizes, copy number aberrations and 4â€mer end motifs in cellâ€free DNA of hepatocellular carcinoma for enhanced liquid biopsyâ€based cancer detection. Molecular Oncology, 2021, 15, 2377-2389.	2.1	14
24	Genetic Polymorphism in a VEGF-Independent Angiogenesis Gene ANGPT1 and Overall Survival of Colorectal Cancer Patients after Surgical Resection. PLoS ONE, 2012, 7, e34758.	1.1	14
25	Genetic variations in genes of metabolic enzymes predict postoperational prognosis of patients with colorectal cancer. Molecular Cancer, 2015, 14, 171.	7.9	12
26	Genetic Variants in the EPCAM Gene Is Associated with the Prognosis of Transarterial Chemoembolization Treated Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. PLoS ONE, 2014, 9, e93416.	1.1	9
27	Polymorphisms of <i>Ep<scp>CAM</scp></i> gene and prognosis for nonâ€smallâ€cell lung cancer in Han <scp>C</scp> hinese. Cancer Science, 2014, 105, 89-96.	1.7	8
28	Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis, 2017, 38, 439-446.	1.3	6
29	Polymorphisms in Genes of Tricarboxylic Acid Cycle Key Enzymes Are Associated with Early Recurrence of Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0124471.	1.1	5
30	High Sensitive and Non-invasive ctDNAs Sequencing Facilitate Clinical Diagnosis And Clinical Guidance of Non-small Cell Lung Cancer Patient: A Time Course Study. Frontiers in Oncology, 2018, 8, 491.	1.3	5
31	Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine. Frontiers in Genetics, 2021, 12, 719451.	1.1	5
32	Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients. Tumor Biology, 2015, 36, 7151-7157.	0.8	3